Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Chongqing Medical University

China · Asia-Pacific

#923World rank of 1,038
26.3ICI scoreout of 100
#147National rank, of 169 in China
#294Regional rank, of 343 in Asia-Pacific
413Verified industry works, 2021 to 2025
214Company groups worked with (69 on two or more works)

Chongqing Medical University is ranked #923 of 1,038. It is held back most by co-creation (8): 413 verified industry works against about 1,166 expected for its mix of fields; and by breadth (22): partners concentrated in a few research fields.

Research Collaboration Index 2026: #755 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
8

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 413 verified works against about 1,166 expected for its fields (0.35 times the expected rate).

Durability20% of the score
35

How much of its industry work sits in sustained partnerships with the same company group. 13 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
42

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 69 company groups on two or more joint works; 13 sustained partnerships.

Breadth20% of the score
22

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (26.3) is the weighted average of the four percentiles. Rank 923 of 1,038 overall; 147 of 169 in China; 294 of 343 in Asia-Pacific. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

1.6%of its 25,047 research works in 2021 to 2025 were co-authored with a verified company
0.35Industry co-authorship rate: 0.35 times what its mix of research fields would predict (413 verified works; about 1,166 expected)
13sustained partnerships: the same company group on five or more joint works in three or more of the five years

In China

147 of 169 ranked universities in China

  1. #145 Shanxi Medical University world #911, score 26.9
  2. #146 Xiangtan University world #911, score 26.9
  3. #147 Chongqing Medical University world #923, score 26.3
  4. #148 Dalian Medical University world #928, score 26.2
  5. #149 Nanjing University of Chinese Medicine world #933, score 25.9

All ranked universities →   Asia-Pacific: 294 of 343 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Strongest sector positions

#255 of 638Pharmaceuticals and Therapeutics116.5 verified works in the sector
Pharmaceuticals and Therapeutics
116.5#255 of 638
Medical Technology and Digital Health
26#295 of 323
Biotechnology and Advanced Therapies
21#214 of 220
Artificial Intelligence
9under 20 works
Advanced Materials and Nanotechnology
3under 20 works
Climate, Environment and Sustainability
2under 20 works
Next-Generation Communications
2under 20 works
Advanced Manufacturing and Industry 4.0
1under 20 works
Agriculture and Food Technology
1under 20 works
Software, Cloud and Data
1under 20 works
Not in any of the 21 sectors
230.5counted in the overall index

182.5 of its 413 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Chongqing Medical University co-authored verified work with 214 company groups, consortium papers aside: 69 of them on two or more works, and 13 as sustained partners.

The largest 12 of its 214 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
Jiangsu Hengrui MedicineChinaMedicine315 of 5
United Imaging HealthcareChinaMedicine30.55 of 5
BGI GroupChinaBiochemistry, Genetics and Molecular Biology17.55 of 5
InferVisionChinaMedicine145 of 5
Keymed Biosciences Inc.ChinaMedicine82 of 5
DanaherUnited StatesMedicine84 of 5
SiemensGermanyEngineering74 of 5
PhilipsNetherlandsEngineering74 of 5
LillyChinaMedicine74 of 5
Bristol-Myers SquibbUnited StatesMedicine63 of 5
State Grid Corporation of ChinaSTATE-OWNEDChinaEngineering62 of 5
PfizerUnited StatesMedicine54 of 5

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.

Over time

Verified industry works by year

392021
592022
64.52023
110.52024
1402025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

9 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07129499 Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas with Jiangsu Famous Medical Technology Co., Ltd., 2025
  • NCT06864962 Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension with Shanghai Hongdian Medical CO., LTD, 2025
  • NCT05911893 the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children with Nestle Health Science, 2024
  • NCT05824923 A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure with Pulnovo Medical (Wuxi) Co., Ltd., 2023
  • NCT06008639 Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease with Danyang Huichuang Medical Equipment Co., Ltd., 2023
  • NCT05755776 The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment with Jiangsu Hansoh Pharmaceutical Co., Ltd., 2023

Evidence checked

523 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 543 of 1,066 candidate links were set aside.

Why links were set aside
  • 240 company name not written in the author's affiliation
  • 107 ordinary-word name without a company suffix
  • 49 part of a university or public institute's own unit
  • 43 not an industry organisation
  • 36 refresh_university_not_on_work
  • 28 a place or common word that failed its stricter rule
  • 40 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where Chongqing Medical University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Chongqing Medical University ranks #755 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.